医学博士，毕业于北京大学医学部，现任北京大学肿瘤医院肝胆胰外一科副研究员。

主要致力于研究消化道肿瘤耐药机制研究，率先发现了核仁介导的细胞器通讯重塑促进肿瘤化疗耐药，以及发现内质网介导的代谢重塑促进TKI类靶向药物耐药。发表SCI论文30余篇，累计他引次数1500余次；主持国家自然科学基金面上项目等科研项目；获中华医学会细胞生物学会优秀论文一等奖。 

代表性成果：

1. 1. Yang Hu, Muhua Chen, Shiqi Sun, Chunfeng Zhang, Zechang Xin, Xiaoyan Sun, Kun Wang, Kemin Jin, Xiaojuan Du, Baocai Xing#, Xiaofeng Liu#. Long non-coding RNA LINC01532 sustains redox homeostasis and accelerates lenvatinib resistance in hepatocellular carcinoma. J Adv Res. 2025 Feb 27:S2090-1232(25)00132-8.

2. Zechang Xin, Chenyu Hu, Chunfeng Zhang, Ming Liu, Juan Li, Xiaoyan Sun, Yang Hu, Xiaofeng Liu#, Kun Wang#. LncRNA-HMG incites colorectal cancer cells to chemoresistance via repressing p53-mediated ferroptosis. Redox Biology (2024) 77: 103362.

3. Yu Wu, Wenyan Han, Hairong Dong, Xiaofeng Liu#, Xiulan Su#. The rising roles of exosomes in the tumor microenvironment reprogramming and cancer immunotherapy. Medcomm. 2024 Apr 7;5(4): e541.

4. Chenyu Hu, Zechang Xin, Xiaoyan Sun, Yang Hu, Chunfeng Zhang, Rui Yan, Yuying Wang, Min Lu, Jing Huang, Xiaojuan Du, Baocai Xing#, Xiaofeng Liu#. Activation of ACLY by SEC63 deploys metabolic reprogramming to facilitate hepatocellular carcinoma metastasis upon endoplasmic reticulum stress. J Exp Clin Cancer Res. 2023 May 1;42(1):108.

5. Muhua Chen, Chunfeng Zhang, Wei Liu, Xiaojuan Du, Xiaofeng Liu#, Baocai Xing#. Long noncoding RNA LINC01234 promotes hepatocellular carcinoma progression through orchestrating aspartate metabolic reprogramming. Molecular Therapy. 2022 Jun 1;30(6):2354-2369.